Somewhat Favorable Media Coverage Somewhat Unlikely to Affect DURECT Corporation (NASDAQ:DRRX) Share Price

News coverage about DURECT Corporation (NASDAQ:DRRX) has been trending somewhat positive this week, Accern reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. DURECT Corporation earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 46.2643458837695 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media stories that may have effected Accern Sentiment’s rankings:

Shares of DURECT Corporation (DRRX) traded up 4.43% during trading on Friday, reaching $1.65. The company’s stock had a trading volume of 781,052 shares. The company has a 50 day moving average price of $1.68 and a 200 day moving average price of $1.21. The firm’s market capitalization is $242.55 million. DURECT Corporation has a 52 week low of $0.74 and a 52 week high of $1.95.

DURECT Corporation (NASDAQ:DRRX) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.02. The business had revenue of $4.32 million during the quarter, compared to analysts’ expectations of $5.17 million. DURECT Corporation had a negative net margin of 221.01% and a negative return on equity of 629.35%. On average, equities research analysts expect that DURECT Corporation will post ($0.21) EPS for the current fiscal year.

A number of brokerages have issued reports on DRRX. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of DURECT Corporation in a research report on Monday, May 22nd. Stifel Nicolaus upgraded DURECT Corporation from a “hold” rating to a “buy” rating and increased their price target for the stock from $1.25 to $3.00 in a research report on Wednesday, July 12th.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect DURECT Corporation (NASDAQ:DRRX) Share Price” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at

About DURECT Corporation

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Insider Buying and Selling by Quarter for DURECT Corporation (NASDAQ:DRRX)

Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply